Dosage and administration
1-10 drops under the tongue, 2 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
1-10 drops under the tongue, 2 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
Oleander 4X, Cicuta virosa 5X, Sulphur 6X, Thuja occidentalis 6X, Hydrocortisone (cortisol) 6X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Vaccinium myrtillus 8X, Bufo rana 10X, Psorinum 10X, Aconitum napellus 12X, Bryonia (alba) 12X, Calcarea sulphurica 12X, Carcinosin 12X, Colibacillnum cum natrum muriaticum 12X, Colocynthis 12X, Medorrhinum 12C, Natrum muriaticum 12X, Secale cornutum 12X, Syphilinum 12X, Sycotic co bacillus 30C.
For the temporary relief of symptoms associated with chronic skin disorders such as warts, itching, and eczema; symptoms of liver damage such as nausea, vomiting, and right upper quadrant pain; and symptoms of depression such as feeling sad, difficulty in concentrating, and inability to focus.
Keep out of reach of children. In case of overdose, contact physician or Poison Control Center right away.
If pregnant or breast-feeding, ask a health professional before use.
Tamper seal: "Sealed for Your Protection." Do not use if seal is broken or missing.
KEEP OUT OF REACH OF CHILDREN. In case of overdose, contact physician or Poison Control Center right away.
1-10 drops under the tongue, 2 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
RX ONLY: Federal law prohibits dispensing without prescription.
For the temporary relief of symptoms associated with chronic skin disorders such as warts, itching, and eczema; symptoms of liver damage such as nausea, vomiting, and right upper quadrant pain; and symptoms of depression such as feeling sad, difficulty in concentrating, and inability to focus.
Demineralized water, 25% Ethanol.
DESBIO
NDC 43742-0437-1
HOMEOPATHIC
BIO PSORINUM PHASE
1 FL OZ (30 ml)
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 43742-0437-1 | 2021-09-21 | C162847 | 48780-1 | 9d75b9d0-a2c4-f424-e053-dadaa90a57ce | Drug Facts |
| 43742-0437-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-a2c4-f424-e053-dadaa90a57ce | Drug Facts |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACONITUM NAPELLUS | ACTIVE INGREDIENT | U0NQ8555JD | 1 | |
| BILBERRY | ACTIVE INGREDIENT | 9P2U39H18W | 1 | |
| BRYONIA ALBA ROOT | ACTIVE INGREDIENT | T7J046YI2B | 1 | |
| BUFO BUFO CUTANEOUS GLAND | ACTIVE INGREDIENT | Q59QU6N72Q | 1 | |
| CALCIUM SULFATE ANHYDROUS | ACTIVE INGREDIENT | E934B3V59H | 1 | |
| CICUTA VIROSA ROOT | ACTIVE INGREDIENT | YEA9P21S8N | 1 | |
| CITRULLUS COLOCYNTHIS FRUIT PULP | ACTIVE INGREDIENT | 23H32AOH17 | 1 | |
| CLAVICEPS PURPUREA SCLEROTIUM | ACTIVE INGREDIENT | 01G9XEA93N | 1 | |
| ENTEROCOCCUS FAECALIS | ACTIVE INGREDIENT | 15E04LZ9CT | 1 | |
| ESCHERICHIA COLI | ACTIVE INGREDIENT | 514B9K0L10 | 1 | |
| GONORRHEAL URETHRAL SECRETION HUMAN | ACTIVE INGREDIENT | 9BZG9E3I8F | 1 | |
| HUMAN BREAST TUMOR CELL | ACTIVE INGREDIENT | C62OO7VD9K | 1 | |
| HYDROCORTISONE | ACTIVE INGREDIENT | WI4X0X7BPJ | 1 | |
| NERIUM OLEANDER LEAF | ACTIVE INGREDIENT | 7KV510R6H6 | 1 | |
| SCABIES LESION LYSATE (HUMAN) | ACTIVE INGREDIENT | 5UAU16Z1U4 | 1 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| SULFUR | ACTIVE INGREDIENT | 70FD1KFU70 | 1 | |
| THUJA OCCIDENTALIS LEAF | ACTIVE INGREDIENT | 0T0DQN8786 | 1 | |
| TREPONEMIC SKIN CANKER HUMAN | ACTIVE INGREDIENT | 4ZWP7FWI8W | 1 | |
| ACONITUM NAPELLUS | ACTIVE MOIETY | U0NQ8555JD | 1 | |
| BILBERRY | ACTIVE MOIETY | 9P2U39H18W | 1 | |
| BRYONIA ALBA ROOT | ACTIVE MOIETY | T7J046YI2B | 1 | |
| BUFO BUFO CUTANEOUS GLAND | ACTIVE MOIETY | Q59QU6N72Q | 1 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 1 | |
| CHLORIDE ION | ACTIVE MOIETY | Q32ZN48698 | 1 | |
| CICUTA VIROSA ROOT | ACTIVE MOIETY | YEA9P21S8N | 1 | |
| CITRULLUS COLOCYNTHIS FRUIT PULP | ACTIVE MOIETY | 23H32AOH17 | 1 | |
| CLAVICEPS PURPUREA SCLEROTIUM | ACTIVE MOIETY | 01G9XEA93N | 1 | |
| ENTEROCOCCUS FAECALIS | ACTIVE MOIETY | 15E04LZ9CT | 1 | |
| ESCHERICHIA COLI | ACTIVE MOIETY | 514B9K0L10 | 1 | |
| GONORRHEAL URETHRAL SECRETION HUMAN | ACTIVE MOIETY | 9BZG9E3I8F | 1 | |
| HUMAN BREAST TUMOR CELL | ACTIVE MOIETY | C62OO7VD9K | 1 | |
| HYDROCORTISONE | ACTIVE MOIETY | WI4X0X7BPJ | 1 | |
| NERIUM OLEANDER LEAF | ACTIVE MOIETY | 7KV510R6H6 | 1 | |
| SCABIES LESION LYSATE (HUMAN) | ACTIVE MOIETY | 5UAU16Z1U4 | 1 | |
| SULFUR | ACTIVE MOIETY | 70FD1KFU70 | 1 | |
| THUJA OCCIDENTALIS LEAF | ACTIVE MOIETY | 0T0DQN8786 | 1 | |
| TREPONEMIC SKIN CANKER HUMAN | ACTIVE MOIETY | 4ZWP7FWI8W | 1 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 43742-0437 | 43742-0437-1 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ALCOHOL | ALCOHOL | 3K9958V90M | ELIXIR / ORAL | 13675 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TOPICAL | 2445 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CAPSULE / ORAL | 882 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / NASAL | 20 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, EMULSION / INTRAVENOUS | 520 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / INTRAVENOUS | 6405 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / NASAL | 70 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / ORAL | 210 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / INTRAVENOUS | 4000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / RESPIRATORY (INHALATION) | 0.08 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / TOPICAL | 561 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / RECTAL | 898 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / NASAL | 10 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | PASTE / DENTAL | 1.8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / NASAL | 20 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / ORAL | 150.68 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAVASCULAR | 100 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / SUBCUTANEOUS | 6.1 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY, METERED / SUBLINGUAL | 29 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LOTION / TOPICAL | 25 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TRANSDERMAL | 90 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVENOUS | 99 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / SUBLINGUAL | 397 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | JELLY / VAGINAL | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TOPICAL | 9971 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAVENOUS | 400 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / BUCCAL | 679 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | POWDER, FOR SOLUTION / TOPICAL | 40 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / ORAL | 6624 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SWAB / TOPICAL | 2250 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SYRUP / ORAL | 21000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAMUSCULAR | 400 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / NASAL | 10 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 35.75 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TRANSDERMAL | 7360 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TOPICAL | 541 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVESICAL | 7892 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TRANSDERMAL | 3675 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAVENOUS | 92 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / SUBCUTANEOUS | 149 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | MOUTHWASH / BUCCAL | 200 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / DENTAL | 12.8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAMUSCULAR | 1491 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / ORAL | 681 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | TABLET, DELAYED RELEASE / ORAL | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / DENTAL | 1.8 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5ad96f5b-622d-48f6-aaa6-cde2773195ed | 2c516866-b1c3-4910-b665-6c20ca21e9af | 2021-09-21 | Warnings | 5ad96f5b-622d-48f6-aaa6-cde2773195ed 2c516866-b1c3-4910-b665-6c20ca21e9af |
Adverse event summaries are temporarily unavailable. Other product information remains available.